These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 8876786)

  • 1. Statistical issues in prevention and therapeutic trials of Alzheimer disease.
    Brookmeyer R; Zeger S
    Alzheimer Dis Assoc Disord; 1996; 10 Suppl 1():27-30. PubMed ID: 8876786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designing a large prevention trial: statistical issues.
    Kryscio RJ; Mendiondo MS; Schmitt FA; Markesbery WR
    Stat Med; 2004 Jan; 23(2):285-96. PubMed ID: 14716729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary prevention trials in Alzheimer disease.
    Green RC; DeKosky ST
    Neurology; 2006 Nov; 67(9 Suppl 3):S2-5. PubMed ID: 17101930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
    Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
    Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of Alzheimer disease.
    Thal LJ
    Alzheimer Dis Assoc Disord; 2006; 20(3 Suppl 2):S97-9. PubMed ID: 16917204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is a randomized trial of antioxidants in the primary prevention of Alzheimer disease warranted?
    Evans DA; Morris MC
    Alzheimer Dis Assoc Disord; 1996; 10 Suppl 1():45-9. PubMed ID: 8876790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention studies in Alzheimer's disease: progress towards the development of new therapeutics.
    Coley N; Gallini A; Andrieu S
    CNS Drugs; 2015 Jul; 29(7):519-28. PubMed ID: 26188654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addressing the challenges of transforming laboratory advances into Alzheimer's Disease treatments.
    Karlawish JH; Clark CM
    Neurobiol Aging; 2002; 23(6):1043-9. PubMed ID: 12470801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials to slow progression and prevent disease onset.
    Thal LJ
    J Neural Transm Suppl; 2000; 59():243-9. PubMed ID: 10961435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priorities for research consortia on Alzheimer's disease.
    Gauthier S; Garcia A; Sano M; Robert P; Senanarong V; Woodward M; Brodaty H
    Alzheimers Dement; 2010 Jul; 6(4):359-62. PubMed ID: 20630416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of comprehensive Alzheimer's disease centers to address unmet national needs.
    Trojanowski JQ; Arnold SE; Karlawish JH; Brunden K; Cary M; Davatzikos C; Detre J; Gaulton G; Grossman M; Hurtig H; Jedrziewski K; McCluskey L; Naylor M; Polsky D; Schellenberg GD; Siderowf A; Shaw LM; Van Deerlin V; Wang LS; Werner R; Xie SX; Lee VM
    Alzheimers Dement; 2010 Mar; 6(2):150-5. PubMed ID: 20298979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention therapeutics of dementia.
    Schneider LS
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S122-30. PubMed ID: 18631988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention trials in Alzheimer disease: one step forward?
    Touchon J; Portet F; Gauthier S
    Neurology; 2006 Nov; 67(9 Suppl 3):S21-2. PubMed ID: 17101931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease modifying trials in Alzheimer disease: methodological and statistical issues.
    Andrieu S; Rascol O; Lang T; Grandjean H; Vellas B
    J Nutr Health Aging; 2006; 10(2):116-7. PubMed ID: 16554944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study design factors and patient demographics and their effect on the decline of placebo-treated subjects in randomized clinical trials in Alzheimer's disease.
    Gold M
    J Clin Psychiatry; 2007 Mar; 68(3):430-8. PubMed ID: 17388715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward.
    Hsu D; Marshall GA
    Curr Alzheimer Res; 2017; 14(4):426-440. PubMed ID: 27697063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dimensional versus nosographic approach to Alzheimer's disease: therapeutic implications.
    Derouesné C; Jouvent R
    Neuroepidemiology; 1990; 9(4):177-82. PubMed ID: 2215841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
    Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
    Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT).
    Meinert CL; Breitner JC
    Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S7-S14. PubMed ID: 18632005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The GuidAge study: methodological issues. A 5-year double-blind randomized trial of the efficacy of EGb 761 for prevention of Alzheimer disease in patients over 70 with a memory complaint.
    Vellas B; Andrieu S; Ousset PJ; Ouzid M; Mathiex-Fortunet H;
    Neurology; 2006 Nov; 67(9 Suppl 3):S6-11. PubMed ID: 17101932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.